LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...

Roughly 1.25 million Americans have Type 1 diabetes, so chances are you know somebody whose pancreas is taking the world’s longest lunch break. That person may be you. As it happens, there has never ...

The Stelo is available to anyone who wants to monitor their blood glucose, no prescription needed. But as an active adult without diabetes, are these extra data points worth $99 per month?

Dexcom will stop producing G6 CGM sensors July 1, 2026, urging patients to switch to the smaller, more accurate G7 model.

DexCom is building increasingly user-friendly devices that continuously monitor blood glucose levels, and a new collaboration between DexCom and Google could lead to the smallest such devices yet.

The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom is preparing to launch a 15-day version of its G7 ...

The US Food and Drug Administration has cleared the Dexcom G7 15-Day Continuous Glucose Monitor (CGM) for people older than 18 with diabetes. It's the longest-lasting system on the market. The G7 ...